Theme
Biotech '25: Commercial / Late Stage☆
APLS-33.58%20.0%
ARQT+18.25%20.0%
CYTK+2.82%20.0%
HALO+68.70%20.0%
SPRY-60.62%20.0%
As of Oct 9, 2026, 4:27 AM ET
Biotech '25: Commercial / Late Stage Constituents
Apellis Pharmaceuticals, Inc.APLS | 20.0% | 0.00% | 0.00% | 0.00% | 0.00% | -31.97% | -18.46% | -25.70% | -33.58% | -37.63% | -48.51% | $2.19B |
Arcutis Biotherapeutics, Inc.ARQT | 20.0% | 1.32% | -10.39% | 2.73% | -3.16% | -15.67% | -9.20% | 47.53% | 18.25% | 153.00% | 9.62% | $3.06B |
ARS Pharmaceuticals, Inc.SPRY | 20.0% | 4.59% | 10.41% | -12.81% | 10.68% | -60.86% | -50.86% | -65.06% | -60.62% | -67.15% | -52.70% | $452.8M |
Cytokinetics, IncorporatedCYTK | 20.0% | 1.46% | -6.27% | -16.33% | -5.50% | -2.41% | -0.34% | 54.06% | 2.82% | 14.14% | 63.14% | $7.72B |
Halozyme Therapeutics, Inc.HALO | 20.0% | -0.86% | -2.70% | 2.28% | 2.71% | 63.21% | 57.97% | 74.29% | 68.70% | 102.92% | 193.22% | $13.03B |
| Theme return | — | 1.30% | -1.79% | -6.38% | 0.66% | -13.58% | -6.60% | 16.84% | -2.36% | 26.51% | 92.65% | — |
| Average | 20.0% | 1.30% | -1.79% | -4.83% | 0.95% | -9.54% | -4.18% | 17.02% | -0.89% | 33.06% | 32.96% | $5.29B |
| Median | 20.0% | 1.32% | -2.70% | 0.00% | 0.00% | -15.67% | -9.20% | 47.53% | 2.82% | 14.14% | 9.62% | $3.06B |
| Std Dev | 0.0% | 1.86% | 7.03% | 8.09% | 5.61% | 41.27% | 35.46% | 53.19% | 44.41% | 83.26% | 90.68% | $4.56B |
| Min | 20.0% | -0.86% | -10.39% | -16.33% | -5.50% | -60.86% | -50.86% | -65.06% | -60.62% | -67.15% | -52.70% | $452.8M |
| Max | 20.0% | 4.59% | 10.41% | 2.73% | 10.68% | 63.21% | 57.97% | 74.29% | 68.70% | 153.00% | 193.22% | $13.03B |
| % Positive Tickers | 60.00% | 20.00% | 40.00% | 40.00% | 20.00% | 20.00% | 60.00% | 60.00% | 60.00% | 60.00% |
Default: Wgt ↓ · Click headers to sort · Shift+click secondaryWgt ↓ · Scroll right · Tap headers to sort